IL7R and acute lymphoblastic leukemia: Likewise, a CD127 (interleukin 7 receptor [IL-7R]) was recently shown to be expressed in a majority of ALL cases, and a CD127-targeted antibody, lusvertikimab, showed potent activity in patient-derived xenograft models [161].